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Suboptimal treatment of human immunodeficiency virus type 1 (HIV-1) infection with nonnucleoside reverse
transcriptase inhibitors (NNRTI) often results in the rapid selection of drug-resistant virus. Several amino
acid substitutions at position 190 of reverse transcriptase (RT) have been associated with reduced suscepti-
bility to the NNRTI, especially nevirapine (NVP) and efavirenz (EFV). In the present study, the effects of
various 190 substitutions observed in viruses obtained from NNRTI-experienced patients were characterized
with patient-derived HIV isolates and confirmed with a panel of isogenic viruses. Compared to wild-type HIV,
which has a glycine at position 190 (G190), viruses with 190 substitutions (A, C, Q, S, V, E, or T, collectively
referred to as G190X substitutions) were markedly less susceptible to NVP and EFV. In contrast, delavirdine
(DLV) susceptibility of these G190X viruses increased from 3 to 300-fold (hypersusceptible) or was only slightly
decreased. The replication capacity of viruses with certain 190 substitutions (C, Q, V, T, and E) was severely
impaired and was correlated with reduced virion-associated RT activity and incomplete protease (PR) pro-
cessing of the viral p55gag polyprotein. These defects were the result of inadequate p160gagpol incorporation into
virions. Compensatory mutations within RT and PR improved replication capacity, p55gag processing, and RT
activity, presumably through increased incorporation of p160gagpol into virions. We observe an inverse rela-
tionship between the degree of NVP and EFV resistance and the impairment of viral replication in viruses with
substitutions at 190 in RT. These observations may have important implications for the future design and
development of antiretroviral drugs that restrict the outgrowth of resistant variants with high replication
capacity.
The nonnucleoside reverse transcriptase inhibitors (NNRTI)
comprise a large group of compounds that are potent inhibi-
tors of human immunodeficiency virus type 1 (HIV-1) replica-
tion (10, 29). The NNRTI are attractive agents for the treat-
ment of HIV-1 infection because they are highly selective,
potent, and relatively nontoxic. Currently, three NNRTI have
received U.S. Food and Drug Administration approval for the
treatment of HIV/AIDS: nevirapine (NVP), delavirdine
(DLV), and efavirenz (EFV). Suboptimal treatment with
NNRTI results in the rapid emergence of drug-resistant virus.
Although structurally diverse, all NNRTI drugs inhibit HIV-1
reverse transcriptase (RT) by binding to a hydrophobic pocket
adjacent to the active site (21, 43, 45). Consequently, NNRTI
resistance is often conferred by RT mutations that compromise
susceptibility to other NNRTI, making subsequent treatments
with this drug class less effective.
NNRTI resistance is associated with mutations within the
NNRTI binding pocket, which includes at a minimum amino
acids (aa) 100 to 110, 180 to 190, and 220 to 240 in RT.
Depending on the NNRTI or whether the NNRTI is used in
combination with other drugs, viruses with different NNRTI
resistance mutation patterns may emerge (5, 26, 27, 34, 35, 38).
In vitro selection of drug-resistant virus with several NNRTI,
including quinoxalines, thiocarboxinilides, or piperazines fre-
quently results in the emergence of HIV-1 containing RT mu-
tations at aa 190 (17). The amino acid substitution that
emerges at position 190 may depend on the degree of selective
drug pressure that is applied (20). Kleim et al. show that, under
strong selective pressure with the NNRTI HBY097, viruses
containing a G190E mutation are selected, whereas viruses
with G190A and G190S mutations emerge in response to lower
drug pressure. Drug-resistant viruses containing G190 substi-
tutions have been reported in patients treated with NVP, EFV,
and MKC-442 in response to treatment (2, 3, 18, 34).
Unlike most NNRTI-resistant viruses, G190E mutant vi-
ruses exhibit severely impaired replication capacity. Other
amino acid substitutions at this position, such as G190A,
G190S, and G190Q, also compromise replication capacity but
to much lesser extents. Several laboratories have previously
reported that the impaired replication of G190E mutant vi-
ruses is due to impaired RT polymerase and RNase H activi-
ties (8, 13, 17, 28). However, the degree of impaired RT func-
tion reported in these studies varies substantially.
In this report we found that certain substitutions at position
190 of RT not only confer resistance to NVP and EFV but also
cause increased susceptibility to DLV. In addition, the studies
described here provide an explanation for the impaired repli-
cation of viruses containing certain G190 substitutions. A bet-
ter understanding of the factors that influence the selection of
G190E versus G190A mutations may aid in the design of more
effective antiretroviral drugs that restrict drug-resistant out-
growth to viruses with severely impaired replication capacity.
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MATERIALS AND METHODS
NNRTI. The NNRTI drugs DLV, EFV, and NVP were generously provided by
Pharmacia-Upjohn (Kalamazoo, Mich.), DuPont Pharmaceuticals (Wilmington,
Del.), and Roxanne Laboratories (Redding, Conn.), respectively.
Phenotypic drug susceptibility testing. Drug susceptibility was measured by
using recombinant viruses and a rapid single replication cycle assay as previously
described (30). Briefly, RT-PCR was used to generate amplification products
(1.5 kb) that include the gag p7/p1 and p1/p6 cleavage sites, the entire protease
(PR) coding region and the RT coding region from aa 1 to 305. To generate
resistance test vectors (RTVs), the amplification products were cloned into an
HIV-1 vector containing a luciferase expression cassette inserted in the env
region. To test patient virus in plasma, RTVs were prepared and tested as large
pools (i.e., PR or RT sequence libraries) to assess the drug susceptibility of virus
populations. Individual clones from these libraries can be prepared as well.
Pseudotyped viruses were produced by cotransfecting 293 (human embryonic
kidney) cell cultures with RTV plasmids plus an expression plasmid encoding the
Env protein of amphotropic murine leukemia virus. High-titer virus stocks were
harvested 48 h after transfection and used to infect fresh 293 target cells in
96-well plates. Serial dilutions of NNRTI drugs were added to individual wells
prior to infection. Approximately 72 h after infection, target cells were lysed and
luciferase activity was measured to assess virus replication in the presence or
absence of drugs at each concentration tested. The percent inhibition was cal-
culated as: [1  (luciferase activity in the presence of the drug/luciferase activity
in the absence of the drug)] 100. The data are displayed by plotting the percent
inhibition of luciferase activity versus the log10 drug concentration. The concen-
tration of drug required to cause a 50% inhibition in virus replication (IC50) was
calculated from the curve fit equation. The fold change in susceptibility is the
ratio the IC50 of the test sample to the IC50 determined for a drug-sensitive
reference virus that was tested in the same experiment. The fold change in
susceptibility measurement in this assay has a reproducibility that is between 1.4-
and 2.3-fold for replicate determinations, depending on the drug being tested
(15).
Virus growth competition assays. Viral stocks of replication competent viruses
were prepared by transfection of 293 cells with 5 g of an infectious proviral
clone of HIV-1. To determine the infectious virus titer, MT2 cells (30,000
cells/well in six replicates) were infected in 96-well plates with serial dilutions of
each infectious virus. Cells were examined for cytopathic effect at day 4 of
culture, and the 50% tissue culture infectious dose (TCID50) was determined by
the method of Reed and Muench (32). Competition assays were performed by
infecting MT2 cells with two viruses in specific ratios (generally, 9:1). Thirty
TCID50 were used to infect 30,000 MT2 cells (multiplicity of infection  0.001).
After 4 h, the culture medium was removed and replaced with fresh medium.
Aliquots of culture supernatants were harvested at serial time points after in-
fection. After 3 to 4 days in culture, 25 l of supernatant from 250 l of culture
was used to infect fresh MT2 cells. The relative proportion of the two viruses in
the culture supernatants was determined at baseline and at serial time points by
measuring the ratio of the peak heights in sequencing chromatograms at one or
more sites that differentiated the two viruses being compared. For example,
wild-type viruses have a GGA triplet coding for G at position 190 in RT. The
G190Q virus has a CAA triplet encoding a glutamine at this same position. The
relative proportion of C or G peaks at the first position of the 190 codon and G
or A peaks at the second position of the 190 codon were determined. The
sensitivity of detection of a minority peak varied from 15 to 20% at all positions
tested. Artificial mixtures between 20 and 80% showed good linearity in this
assay. Relative measures of replication capacity were determined by using a
publicly available web-based software to calculate the selection coefficients (s)
and the relative fitness (1s [where “s” is the selection coefficient]; http://www
-binf.bio.uu.nl/rdb/fitness.html) (24). Calculations were performed at all avail-
able intervals at which the culture consisted of a mixed population (20 to 80%),
and the median value for s and 1s were determined from the distribution of the
calculated values.
Replication capacity testing. Viral replication capacity was measured by using
a modification of the single replication cycle phenotype assay described above
(30). Briefly, recombinant virus stocks were used to infect 293 cells in the absence
of drug. Viruses containing PR and RT sequences derived from resistant viruses
(patient-derived sequences or site-directed mutants) or drug-sensitive reference
virus (NL4-3) were tested. The relative luciferase units (RLU) produced by cells
infected with different viruses was monitored from 6 to 90 h postinfection. The
ratio of luciferase produced by individual viruses compared to the control virus
after infection was relatively constant independent of the time after infection at
which the luciferase was measured. The luciferase activity was routinely mea-
sured at 72 h postinfection. The amount of luciferase activity detected in the
infected cells was used as a direct measure of “infectivity” or “replication capac-
ity,” i.e., the ability of the virus to complete a single round of replication. Three
methods for normalizing the infection data to account for variations in transfec-
tion efficiencies were evaluated: (i) infection with a constant amount of virus
input based on p24, (ii) postinfection normalization based on the amount of p24
in the virus stock, or (iii) postinfection normalization based on the luciferase
activity produced in transfected cells (the RTV transfected into the 293 cells
contains a luciferase expression cassette). All three methods for normalization of
the infection data resulted in similar measures of replication capacity. Normal-
ization was routinely performed by using the transfection luciferase levels. The
replication capacity was calculated as follows: [1  (infection RLUtest virus 
CFTXN)/infection RLUcontrol virus]  100. In this equation, CFTXN is the correc-
tion factor for the transfection efficiency and is calculated by the following
equation: CFTXN  transfection RLUtest virus/transfection RLUcontrol virus. Rep-
lication capacity is expressed as a percentage of the replication capacity of the
reference virus. The in vitro replication capacity measurement has a reproduc-
ibility of 0.2 log for independent measurements. Several independent studies
have compared the in vitro replication capacity assay to virus replication kinetics
assays and in vitro viral growth competition assays (23, 31, 33). Overall, these
studies demonstrate that the rank order of individual viruses is consistent be-
tween data obtained in the single-cycle assay and data from assays employing
replication-competent viruses. However, the absolute value for relative fitness
determined in the assays can differ.
Genotypic analysis. The amino acid sequences of RT were derived from the
DNA sequences of the RTV pools prepared as described above. Sequence
analysis was performed by a thermocycling method using fluorescent dye-labeled
dideoxynucleotide chain terminator chemistry (ABI, Foster City, Calif.). Se-
quencing reaction products were resolved by using a 96 parallel capillary gel
electrophoresis system (ABI 3700). Base calling and amino acid sequence deri-
vations were performed by using customized Sequencher software that performs
automated reference comparison and reporting of amino acid changes compared
to the reference sequence (GeneCodes, Ann Arbor, Mich.). RT amino acid
sequences were compared to those of a reference strain of HIV-1 (NL4-3;
GenBank accession number M19921).
Site-directed mutagenesis and chimeric virus construction. The megaprimer
method of site directed mutagenesis (40) was used to construct a series of
isogenic viruses containing single amino acid substitutions at position 190 of RT,
double amino acid substitutions at positions 190 and 74, or PR and RT active-site
knockout mutations (D25G in PR and D185G in RT). Mutations were intro-
duced directly into the RTV described above as a ApaI/PinAI fragment. For each
mutant, the entire 1.5-kb ApaI/PinAI fragment was sequenced to ensure that
only the desired mutations were present in the viral vectors tested. An RsrII
restriction site was introduced into the RTV at aa 17 and 18 in RT, with silent
mutations at each position (GAT GGC CCA was changed to GAC GGA CCG).
Chimeric viruses were constructed by using the ApaI-RsrII fragment and the
RsrII-PinAI fragment from different parent virus clones to replace the ApaI-
PinAI fragment of the RTV.
In vitro RT measurements. Virion-associated RT elongation activity was mea-
sured by using real-time PCR to quantify the RT-dependent production of a
specific cDNA product from a heteropolymeric RNA template (22). The RT-
PCR takes place in a single position in a 96-well plate. The RNA template is a
3-kb transcript derived from the gag region of the NL4-3 molecular clone of
HIV-1 and was in vitro synthesized by T7 polymerase by use of a standard
transcription protocol (MegaScript T7 kit; Ambion, Inc., Austin, Tex.). Viral
supernatants obtained from transfected 293 cells were lysed in a buffer contain-
ing 0.2% of NP-40, 50 mM Tris HCl (pH 8), 10 mM dithiothreitol, 10 mM MgCl2,
and 50 mM KCl and incubated for 30 min on ice. The lysate was diluted 1/100
with buffer without NP-40, and 5 l was included in the RT-PCR mix (0.3 mM
concentrations of the deoxynucleoside triphosphates, 1 nM concentrations of the
primers [5-TGG ACA TAA GAC AAG GAC CAA and 3-CCA ACA AGG
TTT CTG TCA TC], a 1 nM concentration of probe [AGA GCC GAG CAA
GCT TCA CAG GA], RNase inhibitor [40 U], 10 ng of RNA template, 5 mM of
MgCl2, AmpliTaq Gold (1 U), 1 TaqMan buffer). The reaction was incubated
for 2 h at 37°C for the RT step, incubated 5 min at 95°C to inactivate the viral
RT and activate the AmpliTaq Gold polymerase, and subjected to 40 cycles of
PCR amplification (each cycle consisted of 15 s at 95°C and 90 s at 58°C) (ABI
7700; Applied Biosystems). The RT activity was normalized by p24 antigen
concentration of input viral lysates.
Western blot analysis. To study gag-pol processing, viral stocks were harvested
from 293 cells 2 days after transfection. Virions were pelleted by centrifugation
at 14,000 rpm for 60 min, resuspended in 100 l of sample buffer for gag
processing analysis or in 20 l of sample buffer, and then heated to 100°C for 5
min. Virion proteins were separated by electrophoresis on a 12% sodium dodecyl
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sulfate-polyacrylamide gel and transferred to nitrocellulose membranes. Mem-
branes were blocked by using 5% milk in TBST (0.1% Tween 20, 5 mM Tris-HCl
[pH 8], 100 mM NaCl) and incubated with either a 1:1,500 dilution of rabbit
anti-p24 antisera (obtained through the AIDS Research and Reference Reagent
Program) or a 1:500 dilution of polyclonal antibodies against RT (American
Research Products). After three washes in TBST, the membranes were incu-
bated with 1:1,500 dilution of anti-rabbit immunoglobulin G that was horseradish
peroxidase conjugated (Amersham Life Sciences) and developed by using the
ECL chemiluminescence kit (Amersham Life Science) according to the manu-
facturer’s recommendations.
RESULTS
Mutations at G190 in RT are associated with increased
susceptibility to DLV. Certain mutations in the NNRTI bind-
ing pocket have been shown to differentially affect susceptibil-
ity to the three NNRTI. For example, the Y181C mutation
confers large reductions in susceptibility to NVP and DLV but
has little or no effect on EFV susceptibility (6, 34, 36). In a
large database of phenotypic susceptibility data, we observed a
group of viruses that display 	10-fold reductions in suscepti-
bility to NVP and EFV but remain susceptible (fold change,
0.4 to 2.5) or display increased susceptibility to DLV (fold
change, 
0.4) (Fig. 1). In order to examine whether a specific
mutation or pattern of mutations was associated with de-
creased susceptibility to NVP or EFV and increased suscepti-
bility to DLV, we queried the database containing matched
phenotypes and genotypes (n  4,660). A total of 170 viruses
in this database had the specific phenotype described above
(NVP and EFV, 	10-fold; DLV, 
2.5-fold). Interestingly, a
large percentage of viruses with this phenotypic profile were
found to have mutations at G190 of the RT gene (n 149/170,
i.e., 88%). In contrast, mutations at G190 were observed in
only 15% of the entire database (P 
 0.0001). We observed
several different amino acid substitutions at position 190 in RT.
Previously reported substitutions at 190, including A, S, Q, T,
and E were observed. In addition, we identified viruses with
G190C and G190V. In this database, G190A was the most
common substitution present, accounting for ca. 83% of the
viruses with G190 substitutions (G190S, 15%; G190E, 1%; and
G190Q, G190C, G190T, and G190V, 
1% of viruses with
G190 substitutions). Viruses containing G190X mutations in
combination with additional NNRTI mutations (e.g., at posi-
tions 100, 101, 103, and 181) often displayed reduced suscep-
tibility to DLV. G190 mutations were seen in the database at
approximately the same frequency as Y181 substitutions (15
versus 17%) and about half as frequently as K103 substitutions
(31%). It is also interesting that the population of viruses with
a fold change of 	10 for all three NNRTI is clearly enriched
for the K103 substitution and the population of viruses with
NVP FC and EFV FC values of 
10 is enriched for the Y181
substitution. Other mutations that increase susceptibility to
DLV (e.g., P225H and F227L) have been previously described
(2, 3, 11). These mutations were also observed in our database
at a low frequency (2% each) and were highly enriched in the
viruses with normal or increased susceptibility to DLV.
NNRTI susceptibility profiles for a representative patient-
derived virus containing each of the amino acid substitutions
(A, C, E, Q, S, and V) at 190 of RT are shown in Fig. 2. In all
cases, viruses with substitutions at position 190 exhibited resis-
tance to NVP and EFV ranging from 10-fold to 	600-fold.
190C and 190V were associated with large increases in suscep-
tibility to DLV (100-fold), whereas 190A and 190S are asso-
ciated with more moderate hypersusceptibility (2.5- to 10-
fold). In contrast, 190Q and 190E viruses show low level
reductions in susceptibility (two- to eightfold).
In order to directly determine the effect of different G190
substitutions on NNRTI susceptibility, site-directed mutagen-
esis was used to replace the G190 of the reference virus with
each of the amino acid substitutions observed in the various
patient viruses (A, C, E, Q, S, and V). Each mutant virus was
evaluated for susceptibility to NVP, EFV, and DLV (Table 1).
The NNRTI susceptibility determined for each of the site-
directed mutants was consistent with the NNRTI phenotypic
profiles of the corresponding patient viruses. The NNRTI sus-
ceptibility of the G190E and G190V viruses generated by site-
directed mutagenesis could not be characterized because the
replication of these viruses was severely impaired (see below).
The high concordance in NNRTI susceptibility between the
patient viruses and the site-directed mutants confirms that the
G190 substitutions were primarily responsible for the NNRTI
susceptibility profiles of the patient viruses.
Impaired replication of viruses containing RT mutations at
position 190. It has been previously reported that substitutions
at position 190 of RT result in viruses with lower infectivity in
tissue culture (17, 20, 28). To further evaluate the impact of
these RT mutations on HIV replication, the replication of each
FIG. 1. Classification tree of NNRTI susceptibility. The viruses are
derived from a database, including matched phenotype and genotypes,
from viruses sent to a commercial testing laboratory for routine anti-
retroviral resistance testing. The individual entries of the database are
split into successive branches based on their susceptibility to individual
NNRTI. Viruses are first divided based on having a fold change (FC)
in susceptibility to NVP greater or less than 10-fold compared to a
wild-type reference. Successive splits are for an EFV susceptibility
greater or less than 10-fold and for a DLV susceptibility 
0.4-fold
(hypersusceptible), between 0.4- and 2.5-fold (same as the wild type),
between 2.5- and 10-fold (low-level reductions in susceptibility), and
	10-fold (resistant). The prevalence of viruses with substitutions at
G190, Y181, and K103 are indicated as a percentage of the total in
each of the branches.
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site-directed mutant virus was characterized by using the sin-
gle-cycle replication assay as described above. Viruses contain-
ing different G190 substitutions displayed a wide range of rep-
lication capacities (
0.01 to 83%). The replication capacity of
the G190A virus was only slightly diminished (83%) compared
to the G190 reference virus, whereas the G190S and G190C
viruses were significantly more impaired (21 and 5%, respec-
tively) (Fig. 3A). Viruses with the G190Q, G190T, and G190V
substitutions were severely affected (0.9, 0.05, and 0.01%, re-
spectively). Replication of the G190E virus was too low to
measure with this assay (
0.01%).
Although the replication capacities of the site-directed mu-
tant viruses containing the G190E, G190Q, and G190V sub-
stitutions were extremely low or undetectable, patient-derived
viruses containing these substitutions were able to replicate at
substantially higher levels. The replication capacity of patient-
derived viruses containing 190E, 190Q, and 190V mutations
ranged from 20 to 60% (Fig. 3B). These data suggest that other
amino acid differences in the patient viruses may compensate
for the low replication capacity resulting from the G190X mu-
tations. Compensatory amino acid substitutions can partially
restore the impaired replication capacity of viruses containing
drug resistance mutations (25). In particular, it has been re-
ported that specific mutations at positions 74 and 75 of RT,
which have been associated with NRTI resistance, partially
compensate for mutations at position 190 (8, 19). Consistent
with these earlier observations, all of the viruses carrying the
most deleterious mutations (G190E, G190Q, G190V, and
G190T) in our database also carry either L74 or V75 mutations
and the majority have the L74V substitution.
To measure the effect of an L74V mutation on the replica-
tion capacity of G190X mutant viruses, L74VG190X double
mutants were generated by site-directed mutagenesis and
tested for replication capacity using the single-cycle replication
assay. The L74V mutation alone had no measurable effect on
the replication capacity of the reference virus or on the 190A
virus (Fig. 4). However, L74V increased the replication capac-
ity of viruses with 190S, 190C, 190Q, 190T, and 190V muta-
tions (Fig. 4). Replication of a virus with G190EL74V mu-
tations still could not be measured in this system. As stated
above, susceptibility of the G190V single mutant could not be
determined due to low replication capacity. However, the
G190VL74V double mutant had significantly higher replica-
tion capacity, which allowed an accurate measure of NNRTI
susceptibility (see Table 1). The susceptibility pattern was con-
sistent with patient-derived viruses containing G190V substi-
tutions.
The increased replication capacity observed on G190X vi-
ruses with the L74V mutation was relatively small compared to
the respective patient-derived viruses. An analysis of the RT
and PR sequences of patient-derived viruses containing
G190X mutations revealed numerous mutations and/or poly-
morphisms in these regions (see Fig. 5A). To map the position
of putative compensatory mutations in the patient-derived seg-
ment, chimeric viruses containing either the patient-derived
RT segment or the Gag-PR segment in the NL4-3 reference
backbone were prepared (see Fig. 5). The replication capacity
of recombinant viruses containing only the RT region from the
patient viruses was lower than that of recombinant viruses
containing the entire Gag-PR-RT fragment but higher than
that of the site-directed mutant viruses carrying the respective
190 substitution. This observation suggests that amino acid
substitutions in the Gag-PR segment may also play a role in the
improved replication capacity of patient viruses containing
G190V or G190E mutations. Recombinant viruses carrying
patient-derived Gag-PR regions alone exhibited significantly
higher replication capacities than recombinant viruses with the
FIG. 3. Replication capacity of recombinant viruses with substitu-
tions at aa 190 in RT. The replication capacity is expressed as a
percentage of the reference virus (100%) tested in the same experi-
ment. (A) Site-directed mutant virus clones. The inset plot represents
viruses with low replication capacities (190E, 190Q, and 190V) with a
more sensitive scale. (B) Recombinant virus pools containing patient-
derived PR and RT segments. Recombinant patient-derived viruses
with substitutions at 190E (E1 and E2), 190Q (Q1 and Q2), and 190V
(V1 and V2) are shown.
TABLE 1. Fold change in susceptibility to NNRTI for recombinant
viruses containing substitutions at G190 (patient-derived viruses)
and genetically engineered viruses containing single amino acid
changes at G190 of RT (site-directed mutants)a
Mutation in RT
Phenotypic susceptibility to NNRTIs (fold change)
Site-directed mutants Patient-derived viruses
DLV NVP EFV DLV NVP EFV
190A 0.4 96 7 0.5 134 11
190C 0.01 170 170 0.02 183 111
190Q 6 	600 	270 2.7 	600 270
190S 0.3 191 56 0.18 299 65
190V (L74V) 0.002 600 	270 0.01 	600 	270
190E ND ND ND 5.6 	600 	270
190T 0.04 356 150 NA NA NA
a Changes in NNRTI susceptibility are expressed as the fold change in IC50
based on the IC50 of a drug-susceptible reference virus (IC50 of sample/IC50 of
reference). ND, not determined; NA, not applicable.
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entire Gag-PR-RT fragment. However, the Gag-PR segment
was not sufficient to rescue a virus with a site-directed G190V
or G190E mutation in RT, suggesting that the compensatory
Gag-PR mutations must be in the context of compensatory
mutations in the RT (Fig. 5C). Taken together, these obser-
vations demonstrate that compensatory mutations in both the
RT and Gag-PR regions can contribute to the increased rep-
lication capacity observed in the patient viruses with 190E and
190V mutations.
Replication capacity of viruses with G190 substitutions in
growth competition experiments. To confirm that in vitro rep-
lication capacity measurements derived from the single-cycle
recombinant virus assay were consistent with data generated in
conventional competition assays, we prepared several of the
viruses described in the present study as replication-competent
viral stocks and competed them against each other in replica-
tion assays. The virus stocks were prepared as described above
and used at 9:1 ratios (low RC virus:high RC virus) to infect
MT2 cells. Four competition experiments were performed.
Figure 6 shows the percentages of wild-type and mutant virus
present in the cultures at various time points during the com-
petition, as well as the median (1s) values determined for
each set of competition assays. The relative fitness of the vi-
ruses (190G 	 190S 	 190C 	 190Q) is clear from the time to
reversion in each of the cultures. The increase in the fitness of
the 190Q74V compared to the 190Q alone virus is also
clearly demonstrated by the rapid replacement of the single
mutant by the double mutant in the culture. The relative fitness
determined in the replication competent growth competition
assays is consistent with the replication capacity determined by
using the single-round recombinant virus assay.
RT and PR activity of viruses containing RT mutations at
position 190. Virion-associated RT elongation activity was ex-
amined to further investigate the impaired replication of vi-
ruses containing 190 mutations. The virion-associated RT ac-
tivity measured in viruses carrying G190E, G190V, G190T, and
G190Q substitutions was nearly undetectable. In contrast, the
RT activity of viruses with G190C, G190S, and G190A were 5,
15, and 65%, respectively, compared to the G190 reference
virus (Fig. 7A). Overall, there was a strong correlation between
virion-associated RT activity and replication capacity (com-
pare Fig. 7A with Fig. 3A).
To rule out defects in PR activity associated with viruses
carrying G190X mutations, p55gag processing in virions was
evaluated by Western blot analysis. Normal processing by
HIV-1 PR results in the complete conversion of p55gag to the
matrix (p17MA), capsid (p24CA), nucleocapsid (p17NC), p6, p2,
and p1 proteins. By using an anti-p24CA antibody for analysis,
incomplete processing is evident by the presence of unproc-
essed p55gag protein and the accumulation of a p41MA-CA
intermediate cleavage product. Unexpectedly, in nearly all
cases, viruses containing amino acid substitutions at position
190 of RT exhibited partial p55gag processing (Fig. 7B). The
extent of p55gag processing correlated strongly with viral rep-
lication capacity. The G190 reference virus processed p55gag
completely, and processing in the G190A virus was only slightly
impaired. The G190C and G190S viruses displayed partial
processing, whereas processing in the G190E, G190Q, G190T,
and G190V was severely impaired. These results suggested
that the low replication capacity of viruses carrying a single
mutation at position 190 of RT could be associated with a
defect in PR activity.
Since the HIV-1 PR is also responsible for the conversion of
p160gagpol into the mature PR (p10PR), RT (p66/p51RT), and
integrase (p33IN) proteins, it is possible that the decreased RT
activity associated with G190X mutants is a result of incom-
plete maturation of p160gagpol. To evaluate qualitative or quan-
titative differences in virion-associated RT, the amount of ma-
ture RT protein present in virions was evaluated by using a
polyclonal antibody directed against the RT heterodimer p66-
p51. Using the G190 virus as a reference, reduced p66-p51RT
levels were observed in the site-directed mutant viruses con-
taining amino acid substitutions at position 190 (Fig. 7C). The
G190A virus contained slightly less RT than the G190 refer-
ence virus. Lesser amounts of RT were detected in the G190C
and G190S viruses, whereas RT was nearly undetectable in the
G190E, G190Q, G190T, and G190V mutant viruses. Not sur-
prisingly, the amount of virion-associated RT protein that was
detected correlated very well with virion-associated RT activity
and replication capacity.
There are several possible explanations for the reduced lev-
els of mature RT proteins found in the G190X virions. The
p160gagpol precursor may be degraded in the cytoplasm and
unavailable for virion incorporation, the p160gagpol precursor
may be stable but not efficiently incorporated during assembly,
or the p160gagpol precursor may be incorporated but yet not
appropriately processed. Depending on which explanation is
operable, p160gagpol precursor might be expected to accumu-
late either in the cytoplasm or the virions produced from cells
transfected with G190X vector DNA. The amount of virion-
and cell-associated p160gagpol was examined. In these experi-
ments, a PR active-site mutant (D25G) was used as a reference
for the production and accumulation of the unprocessed
p160gagpol polyprotein. p160gagpol was detected in transfected
cells and in virions with the D25G mutation, however, the
polyprotein was not detected in the G190 reference and
G190X mutant viruses (Fig. 7D). Taken together with the
p66/p51 Western blot data, these results suggest that insuffi-
FIG. 4. Effect of L74V mutations on replication capacity in viruses
containing 190 mutations. Recombinant viruses containing mutated
RT sequences were derived by site-directed mutagenesis of the refer-
ence virus with amino acid substitutions at position 190 with or without
the L74V mutation. Replication capacity was measured in a single
replication cycle assay and is expressed as a percentage of the G190
reference virus. Solid bars represent the relative replication capacity of
G190X viruses. Gray bars represent the relative replication capacity of
the L74VG190X viruses.
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cient incorporation of p160gagpol precursor into virions could
be the cause of low levels of PR and RT.
Patient-derived viruses carrying the mutations G190E,
G190Q, and G190V displayed replication capacities up to 500-
fold higher than the site-directed mutants carrying only the
respective mutation at position 190. Therefore, we analyzed
RT and PR activities and the amount of RT protein in two
patient isolates for each of these three mutant viruses. Both the
FIG. 5. Compensatory mutations improve replication of a patient-derived virus with G190V or G190E substitutions. (A) Amino acid sequences
of PR and RT (aa 1 to 305) are shown for clones derived from two patient isolates carrying the mutation G190V or G190E. The sequence is
reported as the differences from laboratory reference strain NL4-3. (B) Schematic representation of viruses carrying Gag p1 to p6, PR, and RT
sequences from NL4-3 (open bars) or from the individual patient virus clones (shaded bars). Recombinant viruses were constructed by exchanging
Gag-PR and/or RT sequences of the NL4-3 reference virus with the corresponding sequences from patient isolates containing either the G190V
or the G190E mutation. (C) Replication capacity of chimeric viruses. Shaded bars indicate recombinant viruses obtained from patient isolates
carrying the mutation G190V, and the solid bars indicate viruses obtained from patient isolates carrying G190E.
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RT elongation activity and the amount of virion-associated RT
protein were higher than the respective site-directed mutant
(Fig. 8A and B). In addition, Western blot analysis with p24CA
antibody indicated that patient derived viruses accumulated
less unprocessed p55gag, less p41MA-CA intermediate, and more
of the fully processed p24CA protein than the corresponding
site-directed mutant viruses (Fig. 8C). Moreover, consistent
with the observed increases in replication capacity (Fig. 4A),
the addition of an L74V mutation also improved p55gag pro-
cessing of both G190Q and G190V mutant viruses, whereas it
was not able to rescue processing of the G190E mutant (Fig.
8D).
Hypersusceptibility to DLV is associated with increased sus-
ceptibility of RT in vitro. The susceptibility of RT enzymes
derived from the G190 reference virus and three patient virus
clones carrying G190C, G190V, and G190Q substitutions was
evaluated with the RT elongation activity assay in the presence
of different concentrations of DLV (Fig. 9). The IC50s deter-
mined for the RTs were consistent with the IC50s determined
for the viruses. The reference G190 enzyme had an IC50 for
DLV of 0.5 M. The enzymes from viruses with substitutions
at G190C and G190V had IC50s of 0.07 and 0.14 M, respec-
tively, eight- and fourfold lower than the wild-type enzyme. In
contrast, the enzyme from the G190Q virus, was 10-fold less
susceptible to the drug than the G190 reference virus enzyme
(IC50  5 M). All three patient-derived viruses show reduced
levels of RT compared to the G190 reference virus. There is a
very good correlation between the inhibition of the RT in vitro
and the inhibition of the virus replication in culture. However,
the level of DLV susceptibility does not show a perfect corre-
lation with the replication capacity measure or the level of
incorporation of RT into particles. In particular, the G190Q
virus shows low replication capacity and gag-pol incorporation
yet is not hypersusceptible to DLV. These results suggest that
the increased DLV susceptibility observed can be the result of
both stronger interaction with the RT enzyme and less incor-
poration of the protein into the virions.
DISCUSSION
We describe here an NNRTI-phenotypic profile observed in
certain recombinant viruses derived from patient isolates. The
profile, characterized by high-level resistance to NVP and EFV
and hypersusceptibility to DLV, is caused by specific substitu-
tions at position 190 of RT. A wide variety of amino acids were
identified at this position (X  A, S, C, Q, V, T, and E), and
most of them are also associated with impaired viral replica-
tion. Decreased infectivity of the G190X mutant viruses is
associated with decreased RT protein and low RT and PR
activities in the virion; this finding is most likely due to defec-
tive incorporation of p160gagpol into the virions. However, hy-
persusceptibility to DLV imparted by G190 substitutions could
be related to both, a stronger interaction with the RT enzyme
and decreased incorporation of the p160gagpol polyprotein into
the virion.
Previous studies have demonstrated that resistance to
NNRTI drugs, specifically quinoxilanes, carboxanilides, and
piperizines, is conferred by several amino acid substitutions at
position 190 of HIV-1 RT (2, 4, 16, 18, 28). In these studies,
drug-resistant viruses were selected in vitro by serial cultivation
of HIV-1 in the presence of increasing drug concentrations.
These drugs selected different amino acid substitutions under
high or low selective pressure. G190E was often selected at
high drug concentrations, whereas G190A was frequently se-
FIG. 6. Virus growth competition assays. Virus stocks were mixed
at 9:1 ratios and used to infect MT-2 cells, and the percentages of the
two viruses present at various passages after infection were determined
by quantifying the relative peak heights on sequencing chromatograms.
The percentage of allele present at intervals after infection was plotted
for each competition assay. The relative fitness (1s) for each pair (“s”
is the selection coefficient) was calculated as described in Materials
and Methods.
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lected at lower drug concentrations. Several studies have dem-
onstrated that NNRTI treatment in a clinical setting also se-
lects for viruses containing G190X mutations (2, 3, 37). In the
present study, we present data from a large database contain-
ing matched HIV-1 genotypes and phenotypes of viruses de-
rived from patients in clinical practice. In this data set, viruses
with substitutions at G190 were present in 15% of the data set
as a whole. Viruses carrying G190E, G190Q, G190C, G190T,
and G190V mutations were significantly less prevalent than
those carrying G190A and G190S mutations. The striking dis-
parity between the number of G190A and G190E viruses that
emerges in vivo can, at least in part, be explained by the
difference in replication capacity of viruses carrying these mu-
tations. Interestingly, we observed an inverse correlation be-
tween resistance to NVP and EFV and the replication capacity
in viruses containing substitutions at 190 in RT (compare Fig.
2 with Fig. 3). Previous studies have demonstrated that certain
NNRTI resistance mutations (e.g., P236L, Y181C, V179D, and
V106A) are associated with a decreased replicative capacity of
HIV-1 (1, 14). In these studies, the phenotype was shown to be
linked to abnormalities in viral RNase H activity. This could be
through altered folding of the RT protein or direct reposition-
ing of the RNA-DNA duplex through the RNase H domain
such that the RNase H cleavage events would be less efficient
than that of the wild-type RT (39). It is important to note that
we did not evaluate RNase H activity in these experiments, and
the RNase H domain of RT was not included in the patient
derived fragments cloned into the RTVs. Therefore, we cannot
exclude the possibility that additional compensatory mutations
were present in the patient viruses that we did not capture in
our test sequences.
Olmstead et al. reported that G190E viruses replicate less
efficiently than G190 wild-type virus in cell culture (28). In
addition, the recombinant G190E RT protein displayed lower
RT and RNase H activities in vitro (8, 13, 17, 28). In the
present study, we found that viruses with substitutions at po-
sition 190 displayed a wide variety of replication capacities
(
0.01 to 83%), depending on the amino acid present in that
position. Interestingly, patient-derived viruses carrying an
amino acid substitution at position 190 in the context of certain
other mutations or polymorphisms replicated at significantly
higher levels than the respective site-directed mutant, suggest-
ing that compensatory mutations can partially mitigate the
deleterious effect of certain 190 substitutions. This compensa-
tory effect was complex and included mutations in the RT and
in the PR regions (Fig. 5). Bleiber et al. (7) conducted similar
studies on the role of mutations in the PR and RT of patient-
derived HIV-1 on infectivity, replication, RT activity, and pro-
FIG. 7. RT activity and processing of p55gag and p160gagpol polyproteins in viruses containing 190 substitutions. Viral stocks were produced by
transient transfection of 293 cell cultures and normalized by p24 levels prior to analysis. The same stocks were used for all of the analyses shown
in this figure. (A) Virion-associated RT activity measured in viruses with G190A, G190C, G190E, G190Q, G190S, G190T, and G190V is indicated
as a percentage of the reference G190 virus. (B) Processing of virion-associated p55gag. Western blot analysis with anti-p24 antibodies. The mobility
of the viral protein p55gag (p55), the intermediate p17MA-p24CA (p41), and the fully processed p24CA (p24) are indicated with arrows. (C) Pro-
cessing of virion associated p160gagpol. Western blot analysis with anti-RT antibodies. Arrows indicate the position of the p66 and p51 RT proteins.
(D) Virion incorporation of Pr160gagpol. Western blot analysis with polyclonal anti-RT antibodies. Arrow indicates the position of Pr160gagpol
polyprotein. D25G is a virus with a mutation in the active site of PR.
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tein maturation in recombinant viruses in vitro. Consistent
with our findings, these authors reported complex interactions
between PR and RT sequences in their assay and also corre-
lated the presence of certain mutated RTs with impaired fit-
ness and specifically with decreased packaging of p160gagpol
into virions. Carron de la Carriere et al. (9) reported that
recombinant viruses carrying resistant PR sequences from cer-
tain patient viruses showed a reduction in the amount of pack-
aged RT and virion-associated RT activity. In these viruses, the
addition of RT mutations could partially rescue the defect
caused by the patient-derived PR sequences. Kleim et al. re-
ported previously that continued exposure to NNRTI can se-
lect for a secondary mutation either at position L74 or at
position V75 that appeared several passages after the G190X
mutation (19). These mutations had previously been associated
with ddI and ddC resistance. However, in this case they ap-
peared in the absence of NRTI pressure and are clearly linked
to the G190 mutation. In addition, studies with recombinant
proteins demonstrated that the double mutants G190EL74V
and G190EV75I displayed RT and RNase H activities very
similar to the wild-type enzyme (8). In the current study, the
double mutant viruses G190XL74V in most cases replicated
better that the single 190X mutants. However, the replication
capacities of these viruses were still much lower than the ref-
erence G190 virus. The high replication levels of patient-de-
rived recombinant viruses carrying the most deleterious sub-
stitutions at position 190 (E, V, or Q) must be achieved by the
accumulation of multiple secondary mutations that may be
distributed throughout the Gag p1-p6, PR, and RT sequences,
as well as in other regions of the genome not captured in the
assay used in the present study. The L74V mutation was asso-
ciated with an increase in the replication capacity of the
G190Q virus in both the single-cycle replication capacity assay
and the virus growth competition assay; however, the magni-
tude of the effect was much greater in the growth competition
assay than in the single-cycle replication capacity assay. In the
single-cycle replication capacity assay we saw no effect of the
L74V mutation alone on replication capacity. In contrast to
these results, Sharma and Crumpacker (41, 42) reported that
the L74V mutation caused decreased replication when tested
in a virus growth competition assay. It is likely that the virus
growth competition assays are more sensitive to subtle changes
FIG. 8. RT activity and processing of p55gag and p160gagpol polyproteins in patient-derived virus pools containing mutations at position 190 of
RT. Viral stocks were produced by transient transfection of 293 cell cultures and normalized by p24 levels prior to analysis. The same stocks were
used for all of the analyses shown in this figure. (A) Virion-associated RT activity of viruses containing PR and RT sequences from patient isolates
with G190E (patient 190E-1 and patient 190E-2), G190Q (patient 190Q-1 and patient 190Q-2), and G190V (patient 190V-1 and patient 190V-2)
is compared to the RT activity of the site-directed mutants G190E, G190Q, and G190V. (B) Processing of virion associated p160gagpol. Western
blot analysis with anti-RT antibodies. The mobility of molecular weight markers is indicated by the numbers on the left. (C) Processing of virion
associated p55gag. Western blot analysis with anti-p24 antibodies. The mobility of the viral protein p55gag (p55), the intermediate p17MA-p24CA
(p41) and the fully processed p24CA (p24) are indicated with arrows. (D) Processing of virion associated p55gag with site-directed mutants G190E,
G190Q, and G190V with or without a second mutation at position 74 of RT (L74V).
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in replication capacity than the single-cycle assay due to the
potential amplification of subtle differences over many cycles.
In addition, very low replication capacities measured in the
single-cycle replication capacity assay may not correlate with
equally low replication in growth-dependent assays (31, 33).
Previous studies of recombinant RT proteins carrying
G190E, G190Q, G190S, or G190V substitutions used RT ex-
pressed in Escherichia coli with different experimental systems
(8, 13, 28). The enzymatic activity observed with the 190E
enzyme varied from 4 to 60% of the wild-type G190 enzyme. It
was proposed that these discrepancies could be explained ei-
ther by different degrees of purification of the recombinant
proteins or by the presence of improperly folded RT enzyme.
Recombinant RT proteins with 190V, 190Q, and 190S muta-
tions were reported to display slight or no reductions in RT
activity compared to the wild-type G190 enzyme (8, 17). In
contrast, the results presented here indicate that the virion-
associated RT activity of site-directed mutants with 190V,
190Q, and 190S mutations are much lower than that in wild-
type virions (from 1 to 15%). This observation suggests that
there is not a direct correlation between the in vitro activity of
the recombinant protein and the virion associated RT activity.
It is important to note that the amount of mature RT protein
present in virions with G190X mutations explains this lack of
correlation. The results of the present study indicate that re-
ductions in virion-associated RT activity are probably quanti-
tative in nature, although our present studies do not rule out
that there are qualitative differences as well. Viruses with the
lowest replication capacity lacked detectable levels of p66/p51
RT. Western blot analysis demonstrated that the absence of
detectable RT protein in the virion was not associated with
accumulation of the p160gagpol polyprotein in either the virions
or the transfected cells. In addition, viruses with G190X mu-
tations also exhibited poor PR processing of p55gag consistent
with reduced virion incorporation of p160gagpol and low PR
levels. The data generated here are in agreement with a pre-
vious report describing a G190E virus that exhibited reduced
replication capacity and RT activity and had low levels of
p66/p51 RT protein (28). Based on the available data, aberrant
folding of p160gagpol possibly leading to premature degradation
and poor incorporation into virions is a reasonable explanation
for the impaired replication capacity of G190X viruses. In
agreement with this interpretation, it has been reported that
residues 190 and 191 are important for RT protein stability
(44). Interestingly, the increased incorporation of Pol protein
and the improved processing of p55gag observed with the vi-
ruses carrying the double mutation 190XL74V (Fig. 8) sug-
gests that position 74 could directly affect protein stability.
Viruses with G190A, G190C, G190S, G190V, and G190T
substitutions displayed 3- to 300-fold increases in susceptibility
to DLV (Fig. 2 and Table 1). There are several possible bio-
chemical explanations for this phenotype. It is plausible that
the decreased amount of RT protein is limiting for viral rep-
lication, resulting in a virus that is more sensitive to RT inhib-
itors. Alternatively, the mutation at position 190 could result in
tighter binding of DLV, reducing the concentration of drug
necessary for viral inhibition. The susceptibility of the viruses
with G190X substitutions to other RT inhibitors, such as the
ones belonging to the NRTI family (AZT, 3TC, ddI, ddC, and
ABC), indicated that the IC50s were up to twofold lower than
the IC50s for the G190 reference virus (data not shown). This
observation suggests that, even though the low amount of RT
protein could moderately increase the susceptibility to RTIs,
the more profound effect of the G190X substitution on DLV
susceptibility is specific for this drug. More importantly, the
IC50s of DLV of viral RTs carrying G190C or G190V muta-
tions were between four- and eightfold lower than that of the
G190 enzyme, favoring the possibility of a tighter binding to
the drug. In support of this interpretation, structural models
have suggested that the side chain of the amino acid at position
190 could alter the size and shape of the hydrophobic pocket,
resulting in a change in the binding affinity to NNRTI (12, 43).
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